Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN104 in Relapsed/Refractory Acute Leukemia
NCT06052813Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BN104 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL), sponsored by Servier. Started Oct 2023; status: active, not recruiting.
02
Drugs
BN104
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT06052813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052813.